As 2025 draws to a close, columnist Shalom Lim looks back at the highs and lows he's experienced this year while living with ...

The FDA has granted rare pediatric disease designation to (Z)-Endoxifen as a potential treatment for Duchenne muscular ...

During this season of hope, columnist Robin Stemple shares his wishes for both the disability community and himself.

Experimental therapy deramiocel outperformed a placebo at improving measures of arm and heart health in people with DMD in a ...

Columnist Patrick Moeschen argues that we all should focus more on finding the right words to accurately describe living with ...

Upsher-Smith Laboratories launched DMD treatment Kymbee in the U.S., backed by a support program for patients.

Dyne Therapeutics said it plans to ask the U.S. Food and Drug Administration (FDA) to approve DYNE-251, its exon-skipping therapy for people with Duchenne muscular dystrophy (DMD) amenable to exon 51 ...

Doctors can use several tests to diagnose muscular dystrophy (MD). A correct diagnosis gives patients an understanding of how their disease is likely to progress. It also helps doctors do a better job ...

Rob Stemple is a lifelong advocate for people with disabilities. He was diagnosed with FSHD in 1971 at age 14. Rob struggled with its’ affects for over 50 years. He lost his eyesight in a devastating ...

Exon skipping is a treatment approach for people whose Duchenne muscular dystrophy is due to certain mutations in its causative gene. Exon skipping works like a molecular patch, so that the DMD gene ...

It’s hard to believe: This is the 100th column I’ve written for Muscular Dystrophy News Today. It will also be my last for the near future. “Hawk’s-Eye View” has been a part of me for the past three ...

Exon skipping is a treatment approach for people with Duchenne muscular dystrophy (DMD) that, while not a cure, may help to make the effects of the genetic disease less severe. Duchenne, the most ...